In contrast to our study, Calio and colleagues demonstrated that patients with HL who have absent or low expression of p21 and p16 are prone to relapse or do not respond to therapy, as inactivation of tumor suppressor cellular pathways can lead to uncontrolled proliferation, along with the well-known role of EBV in inhibiting p16 expression [18]. This evidence concerns the gene CDKN2A and Hodgkins lymphoma.